Imaging agent for prostate cancer surgery
Part of Cancer clinical trials.
This trial tests a special dye that helps surgeons see prostate cancer cells during surgery. You may be eligible if you are scheduled for prostate removal surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled for prostate removal surgery with or without lymph node removal
- You have agreed to the study and signed a consent form
- You are 18 years or older
- You have a Gleason score of 7 or higher or imaging shows the cancer is stage T2 or higher, or there are enlarged lymph nodes
- Your liver and kidney function are within safe limits
- You have no plans to become pregnant or donate sperm during and for 3 months after the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a dye that makes prostate cancer cells glow during robot-assisted surgery. The goal is to help surgeons remove all the cancer while protecting healthy tissue.
This trial tests a new drug (BMS-986365) combined with another hormone therapy (degarelix) before radical prostatectomy for high-risk prostate cancer. The goal is to see if this combination helps lower cancer activity before surgery.
This trial is testing whether a special scan (PSMA PET/CT) before surgery can help doctors decide if you need to remove lymph nodes. It is for men with high-risk prostate cancer who are already planning to have robot-assisted prostate removal.
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
This trial tests if a special PET scan using PSMA-1007 can find prostate cancer spread in men who have just been diagnosed with high-risk prostate cancer and plan to have surgery. The scan may help doctors better understand the cancer before removing the prostate and lymph nodes.
This study tests a new imaging agent (68Ga-NYM032) used with PET/CT scans to help doctors better detect prostate cancer before surgery. If you have biopsy-confirmed prostate cancer and are planning to have your prostate removed, this trial may help evaluate whether this new imaging method improves cancer detection.
Hear when a new Prostate Cancer Patients Undergoing Radical Prostatectomy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.